246 related articles for article (PubMed ID: 25769717)
1. Targeted therapies in melanoma.
Moschos SJ; Pinnamaneni R
Surg Oncol Clin N Am; 2015 Apr; 24(2):347-58. PubMed ID: 25769717
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy resistance mechanisms and therapeutic implications in melanoma.
Chen G; Davies MA
Hematol Oncol Clin North Am; 2014 Jun; 28(3):523-36. PubMed ID: 24880945
[TBL] [Abstract][Full Text] [Related]
3. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.
Dean E; Lorigan P
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1437-48. PubMed ID: 23249108
[TBL] [Abstract][Full Text] [Related]
4. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.
Jang S; Atkins MB
Clin Pharmacol Ther; 2014 Jan; 95(1):24-31. PubMed ID: 24080641
[TBL] [Abstract][Full Text] [Related]
5. [Molecular alterations in melanoma and targeted therapies].
Mourah S; Lebbé C
Bull Cancer; 2014 Dec; 101 Suppl 2():S5-S11. PubMed ID: 25776766
[TBL] [Abstract][Full Text] [Related]
6. [Targeted therapy of melanoma: fact or fiction?].
Svajdler M; Rychlý B; Benický M
Cesk Patol; 2011 Oct; 47(4):165-7. PubMed ID: 22145215
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy for melanoma: rational combinatorial approaches.
Kwong LN; Davies MA
Oncogene; 2014 Jan; 33(1):1-9. PubMed ID: 23416974
[TBL] [Abstract][Full Text] [Related]
8. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy in melanoma.
Kudchadkar RR; Smalley KS; Glass LF; Trimble JS; Sondak VK
Clin Dermatol; 2013; 31(2):200-8. PubMed ID: 23438383
[TBL] [Abstract][Full Text] [Related]
10. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
Parakh S; Murphy C; Lau D; Cebon JS; Andrews MC
J Clin Pharm Ther; 2015 Feb; 40(1):121-3. PubMed ID: 25382067
[TBL] [Abstract][Full Text] [Related]
11. Melanoma Treatments: Advances and Mechanisms.
Marzuka A; Huang L; Theodosakis N; Bosenberg M
J Cell Physiol; 2015 Nov; 230(11):2626-33. PubMed ID: 25899612
[TBL] [Abstract][Full Text] [Related]
12. New drug targets in metastatic melanoma.
Homet B; Ribas A
J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
[TBL] [Abstract][Full Text] [Related]
13. Genetic alterations and personalized medicine in melanoma: progress and future prospects.
Griewank KG; Scolyer RA; Thompson JF; Flaherty KT; Schadendorf D; Murali R
J Natl Cancer Inst; 2014 Feb; 106(2):djt435. PubMed ID: 24511108
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies for cutaneous melanoma.
Kee D; McArthur G
Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943
[TBL] [Abstract][Full Text] [Related]
15. Systemic treatment for BRAF-mutant melanoma: where do we go next?
Menzies AM; Long GV
Lancet Oncol; 2014 Aug; 15(9):e371-81. PubMed ID: 25079100
[TBL] [Abstract][Full Text] [Related]
16. [Immunotherapies and melanoma].
Routier É; Robert C; Mateus C
Bull Cancer; 2014 Dec; 101 Suppl 2():S13-24. PubMed ID: 25776763
[TBL] [Abstract][Full Text] [Related]
17. Mutation stability in primary and metastatic melanoma: what we know and what we don't.
Varada S; Mahalingam M
Histol Histopathol; 2015 Jul; 30(7):763-70. PubMed ID: 25585249
[TBL] [Abstract][Full Text] [Related]
18. [Targeted molecular therapies (except immunotherapy)].
Roux J; Pages C; Lebbé C
Bull Cancer; 2014 Dec; 101 Suppl 2():S25-36. PubMed ID: 25776764
[TBL] [Abstract][Full Text] [Related]
19. Next-Generation Sequencing to Guide Treatment of Advanced Melanoma.
Griewank KG; Schilling B
Am J Clin Dermatol; 2017 Jun; 18(3):303-310. PubMed ID: 28229402
[TBL] [Abstract][Full Text] [Related]
20. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics.
Lo JA; Fisher DE
Science; 2014 Nov; 346(6212):945-9. PubMed ID: 25414302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]